US Senate clarifies status of interchangeable biosimilar exclusivity

Policies & Legislation/ | Posted 27/05/2022 comments 0
Interchangeability V18K30

The United States (US) Senate Health, Education, Labor and Pensions (HELP) Committee released a draft of the Food and Drug Administration (FDA) Safety and Landmark Advancements Act (FDASLA) on 17 M...

More >
Naming 3 V13J04
Nomenclature of biologicals and biocomparables in Mexico
Posted 18/03/2022

Following the articles on the management and implementation of the nomenclature of biol...

25 AA011049
COVID-19 vaccine produced in Latin America
Posted 18/03/2022

The World Health Organization (WHO) approved a COVID-19 vaccine produced in Latin Ameri...

Biosimilars approved in Colombia
Posted 11/02/2022

In Colombia, the regulatory body for the approval of biologicals is the National Food a...

Home/Non‐Biological Complex Drugs
Liposome V15L11

On 4 April 2018, the US Food and Drug Administration (FDA) issued a new draft guidance...

More >


UK NHS faces drug shortages
Generics/General | Posted 27/05/2022
The cost of developing drugs and use of generics
Generics/Research | Posted 27/05/2022
Repurposing generic drugs can save time and money
Generics/Research | Posted 16/05/2022